secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001171843-24-001877
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose receives Nasdaq deficiency notice for stockholders' equity below $2.5M
-----------------------------------------------------------------------------

- Nasdaq notified Aptose that stockholders' equity as of Dec 31, 2023 was below the $2.5M minimum.
- Company believes subsequent financings on Jan 30-31, 2024 bring equity above the threshold.
- Must submit a compliance plan by May 17, 2024; if accepted, extension up to 180 days from April 2, 2024.
- Alternative listing standards not met: market value below $35M and net income below $500K in last fiscal year.
- Failure could lead to delisting hearing; no immediate effect on Nasdaq Capital Market listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184324001877/0001171843-24-001877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184324001877/f8k_040524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer